Illinois General Assembly - Full Text of Public Act 101-0062
Illinois General Assembly

Previous General Assemblies

Public Act 101-0062


Public Act 0062 101ST GENERAL ASSEMBLY



Public Act 101-0062
HB2259 EnrolledLRB101 09722 KTG 54822 b

    AN ACT concerning public aid.
    Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
    Section 5. The Illinois Public Aid Code is amended by
adding Section 5-30.11 as follows:
    (305 ILCS 5/5-30.11 new)
    Sec. 5-30.11. Medicaid managed care organizations;
preferred drug lists.
    (a) No later than January 1, 2020, the Illinois Department
shall develop a standardized format for all Medicaid managed
care organization preferred drug lists in collaboration with
Medicaid managed care organizations and other stakeholders,
including, but not limited to, organizations that serve
individuals impacted by HIV/AIDS or epilepsy, and
community-based organizations, providers, and entities with
expertise in drug formulary development.
    (b) Following development of the standardized Preferred
Drug List format, the Illinois Department shall allow Medicaid
managed care organizations 6 months from the date of completion
to comply with the new Preferred Drug List format. Each
Medicaid managed care organization must post its preferred drug
list on its website without restricting access and must update
the preferred drug list posted on its website. Medicaid managed
care organizations shall publish updates to their preferred
drug lists no less than 30 days prior to the date upon which
any update or change takes effect, including, but not limited
to, any and all changes to requirements for prior approval
requirements, step therapy, or other utilization controls.
    (c)(1) No later than January 1, 2020, the Illinois
Department shall establish and maintain the Illinois Drug and
Therapeutics Advisory Board. The Board shall have the authority
and responsibility to provide recommendations to the Illinois
Department regarding which drug products to list on the
Illinois Department's preferred drug list. The Illinois
Department shall provide administrative support to the Board
and the Board shall:
        (A) convene and meet no less than once per calendar
        (B) provide regular opportunities for public comment;
        (C) comply with the provisions of the Open Meetings
    All correspondence related to the Board, including
correspondence to and from Board members, shall be subject to
the Freedom of Information Act.
    (2) The Board shall consist of the following voting
members, all of whom shall be appointed by the Governor and
shall serve terms of 3 years without compensation:
        (A) one pharmacist licensed to practice pharmacy in
    Illinois who is recommended by a statewide organization
    representing pharmacists;
        (B) 4 physicians, recommended by a statewide
    organization representing physicians, who are licensed to
    practice medicine in all its branches in Illinois, have
    knowledge of and adhere to best practice standards, and
    have experience treating Illinois Medicaid beneficiaries;
        (C) at least one clinician who specializes in the
    prevention and treatment of HIV, recommended by an HIV
    healthcare advocacy organization;
        (D) at least one clinician recommended by a healthcare
    advocacy organization that serves individuals who are
    affected by chronic diseases that require significant
    pharmaceutical treatments;
        (E) one clinician representing the Illinois
    Department; and
        (F) one licensed psychiatrist, recommended by a
    statewide organization representing psychiatrists, who has
    experience treating Illinois Medicaid beneficiaries.
    One non-voting clinician recommended by an association of
Medicaid managed care health plans shall serve a term of 3
years on the Board without compensation.
    Organizations interested in nominating non-voting
clinicians to advise the Board may submit requests to
participate to the Illinois Department.
    A licensed physician recommended by the Rare Disease
Commission who is a rare disease specialist and possesses
scientific knowledge and medical training with respect to rare
diseases and is familiar with drug and biological products and
treatment shall be notified in advance to attend an Illinois
Drug and Therapeutics Advisory Board meeting when a drug or
biological product is scheduled to be reviewed in order to
advise and make recommendations on drugs or biological
    (d) The Illinois Department shall adopt rules, to be in
place no later than January 1, 2020, for the purpose of
establishing and maintaining the Board.
    Section 99. Effective date. This Act takes effect upon
becoming law.

Effective Date: 7/12/2019